ALLOAllogene Therapeutics, Inc.
$1.24+2.5% 1Y
$1.24
$1.0552 weeks$3.06
Is the price fair?
What ALLO's price assumes
Allogene Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 99.8× revenue.
99.8
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.56
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 1.56
- EV / EBIToperating margin −2636%: the multiple describes the denominator
- not meaningful
- Market capitalisation345.5 million shares, counted Aug 10, 2026
- $428M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.